U.S. Marine and Shipping Stock News

If you are wondering whether Lazard at around US$47.30 represents fair value or a potential bargain, this article breaks down what that price really represents. The stock has seen mixed recent returns, with a 3.5% decline over the last 7 days, a 15.6% gain over the last 30 days, a 4.9% decline year to date and a 27.6% return over the past year, alongside 74.9% and 33.9% returns over 3 and 5 years respectively. These moves sit against an ongoing flow of company and industry updates that...

In recent days, analysts have become more optimistic about LyondellBasell Industries’ upcoming earnings report, revising their profit estimates higher and citing stronger earnings prospects despite a weaker year-on-year comparison. This shift in expectations, supported by favorable third‑party rankings and a more positive view of the petrochemical pricing backdrop, is reshaping how investors assess LyondellBasell’s near-term earnings potential. With analysts raising earnings estimates...

Earlier in April 2026, Bruker expanded its portfolio with the European launch of the MyGenius PRO molecular diagnostics platform, broad enhancements to its MALDI and IR Biotyper microbiology solutions, and new NMR and DNP products targeting higher sensitivity and automation across research and applied workflows. Together, these launches highlight how Bruker is concentrating on higher-throughput, automated, and AI-enabled systems that deepen its presence in infectious disease testing and...

On April 24, 2026, Portland General Electric’s board approved a 5% increase in its quarterly dividend to US$0.55125 per share, payable on or before July 15, 2026, to shareholders of record as of June 25, 2026, aligning with its long-term 60–70% payout ratio target. This dividend increase highlights how PGE is balancing shareholder returns with capital needs for grid modernization and clean energy investment, amid ongoing regulatory and demand shifts. We’ll now examine how PGE’s higher...

Thermon Group Holdings (THR) is back on investor radar after reporting strong order momentum for its liquid load bank products serving data centers, along with higher revenue and adjusted EBITDA guidance and a record backlog. See our latest analysis for Thermon Group Holdings. Thermon’s share price has climbed to $54.18, with a 90-day share price return of 27.36% and a 1-year total shareholder return of 106.16%. This suggests momentum has been building alongside the record backlog and...

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

PennyMac Financial Services and PennyMac Mortgage Investment Trust recently launched the “Welcome Home: Athlete Mortgage Program,” extending specialized mortgage guidance, exclusive benefits, and educational resources to the wider Team USA athlete community in partnership with the U.S. Olympic & Paralympic Committee. The initiative highlights Pennymac’s effort to cultivate a differentiated client base by tailoring lending support to the unique financial profiles of elite athletes. Next,...

There's been a notable change in appetite for Calix, Inc. ( NYSE:CALX ) shares in the week since its quarterly report...

Antero Midstream Corporation ( NYSE:AM ) is about to trade ex-dividend in the next 3 days. The ex-dividend date is one...

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Travere Therapeutics (TVTX) just secured full FDA approval for FILSPARI in focal segmental glomerulosclerosis without nephrotic syndrome, extending its use beyond IgA nephropathy and reshaping how investors may think about the company’s rare kidney portfolio. See our latest analysis for Travere Therapeutics. The FDA decision arrives alongside a sharp 46.95% 1 month share price return and a 37.57% 3 month share price return, while the 1 year total shareholder return of 120.95% points to strong...

Edgewise Therapeutics (EWTX) has drawn investor attention after recent trading left the stock around $31.58, with returns showing mixed short term moves but a strong year to date and 1 year profile. See our latest analysis for Edgewise Therapeutics. Recent trading has been choppy, with a 1 day share price return of 1.12% and a 7 day share price return of an 8.28% decline. However, momentum over the past 90 days and year to date remains positive, supported by a 1 year total shareholder return...

Atomera Incorporated recently announced it has expanded its long-running collaboration with Synopsys to develop gallium nitride (GaN) device modeling workflows for radio frequency and power semiconductor applications using Synopsys’ Sentaurus TCAD and Atomera’s MSTcad toolset. This move extends Atomera’s MST modeling capabilities into GaN, potentially deepening its role in high-value RF and power markets by integrating more tightly into Synopsys’ widely used design ecosystem. We’ll now...

Evolv Technologies Holdings, Inc. recently announced multi-year subscription agreements and marketing partnerships with the University of Washington’s athletic department and Crypto.com Arena, expanding deployments of its Evolv Express Gen2 and eXpedite AI-based screening systems across major college and professional sports venues. These high-traffic stadium and arena wins highlight growing adoption of Evolv’s subscription-based security platforms in sports and entertainment, reinforcing its...

The American Academy of Dermatology’s new pediatric guidelines give a strong, evidence-backed endorsement to Arcutis Biotherapeutics (ARQT) lead product ZORYVE for children with mild to moderate atopic dermatitis, highlighting efficacy, safety, and long-term use. See our latest analysis for Arcutis Biotherapeutics. At a share price of $23.26, Arcutis has a 1 day share price return of 1.75%, while the year to date share price return of 19.79% decline contrasts with a 1 year total shareholder...

Recent performance and context for W.W. Grainger W.W. Grainger (GWW) has drawn fresh investor attention after recent share price moves, with the stock showing mixed short term returns but positive performance over the month and the past 3 months. See our latest analysis for W.W. Grainger. Recent trading has been slightly softer, with a 1-day share price return of 1.45% and a 7-day share price return of 1.29%. That sits against a 30-day share price return of 6.7% and a 1-year total shareholder...

Recent share performance and business snapshot Lucky Strike Entertainment (LUCK) has drawn attention after a recent pullback, with the share price closing at US$7.24 as investors reassess the business following its rebrand from Bowlero Corp. The company runs a portfolio of bowling centers and entertainment venues across North America, including AMF, Bowl America, Lucky Strike, Bowlero, Octane Raceway, several water parks, and Boomers Parks. It has reported revenue of US$1,240.203 million and...

SkyWest (SKYW) has kicked off Q1 2026 with total revenue of US$1.0b, basic EPS of US$2.54 and net income of US$101.7 million, setting the tone for its latest set of results. The company has seen quarterly revenue move from US$948.5 million in Q1 2025 to US$1.0b in Q1 2026, while basic EPS has shifted from US$2.48 to US$2.54 over the same period, against a backdrop of trailing 12 month EPS of US$10.69 and net income of US$429.5 million. With a trailing net margin of 10.4% versus 9.9% the prior...

Wondering if Atlas Energy Solutions at around US$16.31 offers good value for your money? This article focuses on what the current share price might mean for long-term investors. The stock has shown sharp recent moves, with returns of 22.7% over 7 days, 20.3% over 30 days, 67.8% year to date and 19.1% over the past year. These figures can change how you think about both potential upside and risk. Recent coverage has centered on Atlas Energy Solutions as investors reassess US energy services...

Why Caris Life Sciences Is On Investors’ Radar Caris Life Sciences (CAI) has attracted fresh attention after recent share price moves, with the stock up about 10% over the past month but showing a roughly 19% decline over the past 3 months. See our latest analysis for Caris Life Sciences. The recent 10.2% 30 day share price return stands against a 19.2% 90 day decline and a 25.1% year to date share price fall, indicating fading momentum despite the latest move. If Caris’s recent swings have...

A new product liability lawsuit alleges a design flaw in Newell Brands' CrockPot Express Crock Multicooker led to severe burn injuries when the lid opened while still under pressure. The case targets Newell Brands, listed as NasdaqGS:NWL, and focuses on product safety controls and consumer protection around its popular small appliance line. Newell Brands, through its CrockPot range, is a familiar name in many kitchens, so any allegation around product safety can quickly draw attention from...

Why Callaway Golf (CALY) Is Back in Focus Callaway Golf (CALY) is on investors’ radar after a recent name change from Topgolf Callaway Brands Corp. This shift has refocused attention on its core golf equipment and apparel business and how that mix supports current valuation. See our latest analysis for Callaway Golf. The share price at US$15.31 reflects a strong year to date share price return of 30.63%, while the 128.17% total shareholder return over one year contrasts with weaker three and...

AtaiBeckley reported detailed Phase 2a data for its oral R-MDMA candidate EMP-01 in adults with Social Anxiety Disorder. The trial showed strong and consistent efficacy, with meaningful improvements in clinician- and patient-reported symptoms and real world behavioral outcomes. EMP-01 was found to be safe and well tolerated, with high participant retention and no serious adverse events, and the results were achieved without adjunctive psychotherapy. For AtaiBeckley, listed on NasdaqGM:ATAI,...

Amneal Pharmaceuticals (NasdaqGS:AMRX) has agreed to acquire Kashiv BioSciences, creating a fully integrated global biosimilars platform. The transaction is expected to accelerate Amneal's biosimilar pipeline and support multiple planned biosimilar launches over the coming years. The combination brings together Kashiv's development capabilities with Amneal's commercial infrastructure and established generics franchise. Amneal Pharmaceuticals, trading at around $12.52, has seen a very large...